Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GJB2 | P29033 | 7/20 | 0.46 |
| ▸ | LGALS8 | O00214 | 3/20 | 0.41 |
| ▸ | LGALS3 | P17931 | 3/20 | 0.41 |
| ▸ | LGALS4 | P56470 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | GJA1 | P17302 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | IGF2R | P11717 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SYNJ2 | O15056 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15028629 | 0.87 | MAPK1 (0.55) | GJB2LGALS8LGALS3LGALS4MAPK1 | |
| SCHEMBL16153926 | 0.82 | SLC6A2 (0.47) | GJB2GJA1SYNJ2 | |
| SCHEMBL4203209 | 0.77 | GBA1 (0.36) | GJB2MAPK1LMNA | |
| SCHEMBL28276199 | 0.73 | MAPK1 (0.38) | MAPK1IGF2R | |
| SCHEMBL28274780 | 0.73 | MAPK1 (0.38) | MAPK1IGF2R | |
| SCHEMBL28276205 | 0.73 | MAPK1 (0.38) | MAPK1IGF2R | |
| SCHEMBL28274791 | 0.73 | MAPK1 (0.38) | MAPK1IGF2R | |
| SCHEMBL13977483 | 0.73 | LGALS8 (0.60) | GJB2LGALS8LGALS3LGALS4MEN1 | |
| SCHEMBL16204127 | 0.73 | LGALS8 (0.60) | GJB2LGALS8LGALS3LGALS4MEN1 | |
| SCHEMBL8773131 | 0.73 | LGALS3 (0.72) | GJB2LGALS8LGALS3LGALS4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140303363-A1 | Preparation and Use of Isolactosamine and Intermediates therefor | GLYCOM A/S (DK) | 2014-10-09 | — | — | US | disclosed |
| WO-2013083136-A1 | PREPARATION AND USE OF ISOLACTOSAMINE AND INTERMEDIATES THEREFOR | GLYCOM A/S (DK) | 2013-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303363-A1 | Preparation and Use of Isolactosamine and Intermediates therefor | GALE, B4GALT1, GNE | GJB2 1285/4885LGALS8 26/4885LGALS3 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.